| ［1］Zhang X,Lin G,Tan L,et al.Current progress of tacrolimus dosing in solid organ transplant recipients:Pharmacogenetic considerations［J］.Biomed Pharmacother,2018,102:107-114.
［2］Meng Yu,Mouze Liu,Wei Zhang,et al.Pharmacokinetics, pharmacodynamics and pharmacogenetics of tacrolimus in kidney transplantation［J］.Curr Drug Metab,2018,19(4):513-522.
［3］Jasiak NM, Park JM.Immunosuppression in solid-organ transplantation essentials and practical tips［J］.Crit Care Nurs Q,2016,39(3):227-240.
［4］Fernández-Ramos AA, Poindessous V, Marchetti-Laurent C, et al.The effect of immunosuppressive molecules on T-cell metabolic reprogramming［J］.Biochimie,2016,127:23-36.
［5］Liu F,Wang YQ,Meng L,et al.FK506-binding protein 12 ligands: a patent review［J］.Expert Opin Ther Pat，2013,23(11):1435-1449.
［6］李学旺.成人原发性肾病综合征治疗专家共识［M］.北京:人民卫生出版社,2011.
［7］Zhu P,Zhou FD,Wang SX,et al.Increasing frequency of idiopathic membranous nepgropathy in primary glomerular disease:A 10-year renal biopsy study from a singal Chinense nephrology centra［J］.Nephrology,2015,20(8):560-566.
［8］Xu X,Wang G,Chen N,et al.Long-term exposure to air pollution and increased risk of membranous nephrology in China［J］.J Am Soc Nephrol,2016,27(12)：3739-3746.
［9］黎磊石，刘志红.中国肾脏病学［M］.北京:人民军医出版社，2008,403-417.
［10］江罗佳，冯益宇，房向东，等.他克莫司与环磷酰胺比较治疗特发性膜性肾病的系统评价［J］.实用医学杂志，2014，30(1):121-126.
［11］高春寿，焦军东，李春媚，等.他克莫司和霉酚酸酯分别联合激素治疗特发性膜性肾病Ⅲ期疗效比较［J］．临床内科杂志，2013，30(1):44-47.
［12］Meyrier A.An update on the treatment options for focal segmental glomerulosclerosis［J］.Expert Opin Pharmacother，2009，10( 4) : 615-628.
［13］Duncan N，Dhaygude A，Owen J，et al.Treatment of focal and segmental glomerulosclerosis in adults with tacrolimus monotherapy［J］.Nephrol Dial Transplant，2004,19(12):3062-3067.
［14］Li X，Lv R，He Q，et al.Early initiation of tacrolimus or cyclophosphamide therapy for idiopathic membranous nephropathy with severe proteinuria［J］．J Nephrol，2008，21(4): 584-591.
［15］Bhimma R，Adhikari M，Asharam R，et al.Management of steroid-resistant focal segmental glomerulosclerosis in children using tacrolimus［J］.Am J Nephrol，2006，26(6):544-551.
［16］He L，Peng Y，Liu H，et al.Treatment of idiopathic membranous nephropathy with combination of low-dose tacrolimus and corticosteroids［J］．J Nephrol，2013，26(3):564-571．
［17］于锐，田密，刘大军，等．他克莫司联合小剂量激素治疗成人激素依赖或激素抵抗微小病变肾病的疗效［J］．实用药物与临床，2012，15(6): 334-337．
［18］孙雪峰, 陈香美.他克莫司在原发性肾病综合征治疗中的应用［J］.中国实用内科杂志, 2008，28(5):323-325.
［19］Ponticelli C, Glassock RJ. Glomerular diseases: membranous nephropathy-a modern view［J］. Clin J Am Soc Nephrol, 2014 ，9(3):609-616.
［20］ Angioi A, Lepori N, López AC， et al. Treatment of primary membranous nephropathy: where are we now［J］? J Nephrol, 2018,31(4):489-502.
［21］Kronbichler A, Oh J, Meijers B, et al.Recent progress in deciphering the etiopathogenesis of primary membranous nephropathy［J］.BioMed Res Int, 2017:1936372.
［22］Rauch MC，Sanmartna A，Ojeda D，et al.Tacrolimus causes a blockage of protein secretion which reinforces its immunosuppressive activity and also explains some of its toxic side-effects［J］.Transpl Immunol，2009，22(1-2):72-81.
［23］Aaltonen S，Honkanen E.Outcome of idiopathic membranous nephropathy using targeted stepwise immunosuppressive treatment strategy［J］. Nephrol Dial Transplant，2011,26 (9):2871-2877.
［24］Kidney Disease: Improving Global Outcomes ( KDIGO) Glomerulophritis Work Group.KDIGO Clinical Practice Guideline for Glomerulonephritis ［J］.Kidney Inter Suppl，2012，2(2):139-274.
［25］Qin HZ,Liu L,Liang SS,et al.Evaluating tacrolimus treatment in idiopathic membranous nephropathy in a cohort of 408 patients［J］. BMC Nephrol,2017, 18(1):2.
［26］Praga M, Barrio V, Juárez GF,et al.Tacrolimus monotherapy in membranous nephropathy: A randomized controlled trial［J］. Kidney Int，2007,71 (9): 924-930.
［27］Liu S, Li X, Li H, et al.Comparison of tripterygium wilfordii multiglycosides and tacrolimus in the treatment of idiopathic membranous nephropathy: a prospective cohort study［J］.BMC Nephrol，2015,16:200.
［28］Ramachandran R, Hn HK, Kumar V，et al. Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial［J］.Nephrology,2016,21 (2): 139-146.
［29］徐平，何雨荻，于泽铭，等.环孢素A和他克莫司治疗特发性膜性肾病的有效性及安全性比较：网状Meta分析［J］.中国医学科学院学报，2018,40（1）:41-51.
［30］Liu JY,You RX,Guo M,et al.Tacrolimus versus cyclosporine as primary immunosuppressant after renal transplantation: a meta-analysis and economics［J］.Am J Ther,2016,23(3):e810-e824.
［31］Qiu TT,Zhang C,Zhao HW,et al.Calcineurin inhibitors versus cyclophosphamide forIdiopathic membranous nepgropathy:a systematic review and Meta-analysis of 21 clinical trials ［J］.Autoimmun Rev,2016,16(2):136-145.
［32］Zhu LB,Liu LL,Yao L,et al.Efficacy and Safety of tacrolimus versus cyclophosphamide for primary membranous nephropathy: a meta-analysis［J］. Drugs,2017，77(2):187-199.
［33］Ren S, Wang Y, Xian L,et al.Comparative effectiveness and tolerance of immunosuppressive treatments for idiopathic membranous nephropathy: A network meta analysis［J］.Plos one,2017,12(9):e0184398.
［34］Liang Q,Li H,Xie XS,et al.The efficacy and safety of tacrolimus monotherapy in adult-onset nephritic syndrome caused by idiopathic membranous nephropathy［J］.Ren Fail,2017,39(1):512-518.
［35］Peng L,Wei SY,Li LT,et al.Comparison of different therapies in high-risk patients with idiopathic membranous nephropathy［J］.J Formos Med Assoc,2016,115(1):11-8.
［36］Ramachandran R, Hn HK, Kumar V,et al.Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy:Randomized control trial［J］.Nephrology (Carlton),2016,21(2):139-146.
［37］陈丽,季宗雯,孙宝光.他克莫司治疗膜性肾病患者疗效及其对血肌酐、血清白蛋白、24 h尿蛋白定量等的影响［J］.疑难病杂志, 2016，15(22):1238-1241.
［38］Lin G,Zhang X,Zhang K,et al.Evaluation of tacrolimus-related CYP3A5 genotyping in china:results from the first external quality assessment exercise［J］.J Clin Lab Anal,2018,32(8):e22563.
［39］Htun YY,Swe HK,Saw TM.CYP3A5*3 Genetic polymorphism and tacrolimus concentration in myanmar renal transplant patients［J］.Transplant Proc,2018,50(4):1034-1040.
［40］Chen D,Hou S,Zhao M,et al.Dose optimization of tacrolimus with therapeutic drug monitoring and CYP3A5 polymorphism in patients with myasthenia gravis［J］.Eur J Neurol,2018,25(8):1049-e80.
［41］Liu J,Ouyang Y,Chen D,et al.Donor and recipient P450 gene polymorphisms influence individual pharmacological effects of tacrolimus in Chinese liver transplantation patients［J］.Int Immunopharmacol,2018,57:18-24.
［42］Hu C,Yin WJ,Li DY,et al.Evaluating tacrolimus pharmacokinetic models in adult renal transplant recipients with different CYP3A5 genotypes［J］. Eur J Clin Pharmacol,2018,74(11):1437-1447.
［43］Uno T,Wada K,Matsuda S,et al.Impact of the CYP3A5*1 allele on the pharmacokinetics of tacrolimus in japanese heart transplant patients［J］. Eur J Drug Metab Pharmacokinet,2018,43(6):665-673.
［44］Soda M,Fujitani M,Michiuchi R,et al.Association Between Tacrolimus Pharmacokinetics and Cytochrome P450 3A5 and Multidrug Resistance Protein 1 Exon 21 Polymorphisms［J］.Transplant Proc,2017,49(6):1492-1498.
［45］Dennis A.Hesselink,et al.Genetic polymorphisms of the CYP3A4,CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus［J］. Clin Pharmacol Ther，2003，74(3):245-254.
［46］张月丽,明英姿,周宏灏,等.他克莫司：药代动力学，药效动力学和药物基因组学［J］.中国临床药理学与治疗学,2014,19(9):1042-1050.
［47］朱琳,华之卉,宋洪涛.他克莫司的药物基因组学与个体化用药［J］.中国临床药理学与治疗学, 2011,16(6):710-715.
［48］Huang W，Lin YS，McConn DJ，et al. Evidence of significant contribution from CYP3A5 to hepatic drug metabolism［J］. Drug Metab Dispos，2004，32（12）：1434.
［49］Kuehl P，Zhang J，Lin Y，et al.Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression［J］. Nat Gene,2001,27（4）：383.
［50］Hu YF, He J, Chen GL, et al. CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in Chinese population［J］. Clin Chim Acta,2005,353(1/2):187-92.
［51］侯明明, 侯颖, 宋洪涛, 等.肾移植患者CYP3A4 基因多态性对他克莫司疗效和不良反应的影响［J］.中国药房, 2010 ,21(26):2427-2429.
［52］Hoffmeyer S , Burk O , von Richter O , et al.Functional polymorphisms of the human multidrug resistance gene : multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo［J］. Proc Natl Acad Sci USA,2000,97(7):3473.
［53］许向阳,朱家壁.群体药动学的研究进展及应用［J］.中国医院药学杂志, 2007,27(4):521-523.
［54］谭昀杜熙,李玉珍.遗传药理学的基本内容和研究进展［J］.中国执业药师, 2009,6(10):3-9.
［55］Reséndiz-Galván JE, Medellín-Garibay SE, Milán-Segovia RDC，et al.Dosing recommendations based on population pharmacokinetics of tacrolimus in mexican adult patients with kidney transplant［J］.Basic Clin Pharmacol Toxicol,2018，27.doi: 10.1111/bcpt.13138.
［56］Zhu W, Xue L, Peng H,et al.Tacrolimus population pharmacokinetic models according to CYP3A5/CYP3A4/POR genotypes in Chinese Han renal transplant patients［J］.Pharmacogenomics,2018,19(13):1013-1025.
［57］Hao GX,Huang X,Zhang DF,et al.Population pharmacokinetics of tacrolimus in children with nephrotic syndrome［J］.Br J Clin Pharmacol,2018,84(8):1748-1756.
［58］Woillard JB,Saint-Marcoux F,Debord J,et al.Pharmacokinetic models to assist the prescriber in choosing the best tacrolimus dose［J］.Pharmacol Res,2018,130:316-321.
［59］左笑丛,袁洪,张毕奎.用模型和模拟方法设计氨氯地平的群体药动学研究方案［J］.药学学报,2012,47(7):941-946.
［60］Andreu F, Colom H, Grinyó JM, et al. Development of a population PK model of tacrolimus for adaptive dosage control in stable kidney transplant patients［J］.Ther Drug Monit,2015,37(2):246-255.
［61］张关敏,李良,陈文倩.他克莫司在中国肾移植患者中的群体药物动力学研究［J］.药学学报,2008,43(7):695-701. |
